[1]曹莉明,张勇学,梁志会,等.载药微球栓塞治疗传统TACE抵抗的原发性肝癌临床疗效[J].介入放射学杂志,2023,32(01):59-62.
　CAO Liming,ZHANG Yongxue,LIANG Zhihui,et al.Drug-eluting beads-trancatheter arterial chemoembolization for the treatment of hepatocellular carcinoma refractory to conventional transcatheter arterial chemoembolization: observation of its clinical effect[J].journal interventional radiology,2023,32(01):59-62.
点击复制

载药微球栓塞治疗传统TACE抵抗的原发性肝癌临床疗效()

PDF下载中关闭

分享到：

《介入放射学杂志》[ISSN:1008-794X/CN:31-1796/R]

卷:
32
期数:
2023年01
页码:
59-62
栏目:
临床研究
出版日期:
2023-02-13

文章信息/Info

Title:
Drug-eluting beads-trancatheter arterial chemoembolization for the treatment of hepatocellular carcinoma refractory to conventional transcatheter arterial chemoembolization: observation of its clinical effect
作者:
曹莉明; 　张勇学; 　梁志会; 　李　亮; 　崔进国
Author(s):
CAO Liming;  ZHANG Yongxue;  LIANG Zhihui;  LI Liang;  CUI Jinguo.
Department of Interventional Therapy, No.980 Hospital of PLA Joint Logistics Support Forces （Bethune International Peace Hospital）, Shijiazhuang, Hebei Province 050082, China
关键词:
【关键词】原发性肝癌; TACE抵抗; 肝硬化; 肝动脉化疗栓塞术; 载药微球
文献标志码:
A
摘要:
【摘要】　目的　评价载药微球经导管动脉化疗栓塞（drug-eluting beads-trancatheter arterial chemoembolization，DEB-TACE）治疗对传统导管动脉化疗栓塞（transcatheter arterial chemoembolization，TACE）抵抗的原发性肝癌的安全性及有效性。方法　回顾分析2017年1月至2021年1月解放军联勤保障部队第九八〇医院对传统TACE抵抗的原发性肝癌行DEB-TACE治疗25例患者的临床资料，采用改良实体瘤疗效评价标准（ mRECIST）统计分析临床疗效，比较治疗前后肝功能变化，记录并发症发生情况。结果　25例患者共实施DEB-TACE治疗36例次，栓塞终点为肿瘤染色消失，供血动脉闭塞。根据mRECIST标准，DEB-TACE术后1个月、3个月和6个月患者的客观缓解率（ORR）分别为92%、72%和60%，疾病控制率（DCR）分别为96%、88%和80%。DEB-TACE术后第3天，AST和ALT升高，差异有统计学意义（P＜0.05），术后7 d逐步好转，术后30 d恢复至术前水平，与术前比较差异无统计学意义（P＞0.05）。总胆红素及白蛋白变化不大，治疗前后差异无统计学意义（P＞0.05）。未出现肝衰竭、肝脓肿及骨髓抑制等严重并发症。结论　DEB-TACE治疗对传统TACE抵抗的中期原发性肝癌安全、有效。

参考文献/References:

［1］　Llovet JM, Kelley RK, Villanueva A. Hepatocellular carcinoma［J］. Nat Rev Dis Primers, 2021, 7:6.
［2］　魏矿荣，彭侠彪，梁智恒，等. 全球肝癌流行概况［J］. 中国肿瘤，2015，24：621-630．
［3］　European Association for the Study of the Liver. Corrigendum to "EASL Clinical Practice Guidelines: management of hepatocellular carcinoma" ［J Hepatol 69 （2018） 182-236］［J］. J Hepatol, 2019,70:817.
［4］　吴孟超，汤钊猷，刘允怡，等. 原发性肝癌诊疗规范（2019 年版）［J］. 中华消化外科杂志，2020，19：1-2．
［5］ Kokudo N, Takemura N, Hasegawa K, et al. Clinical practice guidelines for hepatocellular carcinoma: The Japan Society of Hepatology 2017 （4th JSH‐HCC guidelines） 2019 update［J］. Hepatol Res, 2019, 49: 1109-1113.
［6］ Marelli L, Stigliano R, Triantos C, et al. Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies［J］. Cardiovasc Intervent Radiol, 2006, 30: 6-25.
［7］　余晨曦，滕皋军. 经导管动脉化疗栓塞术抵抗研究进展［J］. 介入放射学杂志，2017，26：1063-1067．
［8］ Kajihara J, Tomimaru Y, Eguchi H, et al. The clinical impact of transcatheter arterial chemoembolization （TACE）-induced c-Met upregulation on TACE refractoriness in hepatocellular carcinoma［J］. Dig Dis Sci, 2016, 61: 1572-1581.
［9］ Kudo M, Matsui O, Izumi N, et al. Transarterial chemoembolization failure/refractoriness: JSH-LCSGJ criteria 2014 update［J］. Oncology, 2014, 87（Suppl 1）: 22-31.
［10］ Ikeda M, Mitsunaga S, Shimizu S, et al. Efficacy of sorafenib in patients with hepatocellular carcinoma refractory to transcatheter arterial chemoembolization［J］. J Gastroenterol, 2014, 49: 932-940.
［11］ Chen P, Yuan P, Chen B, et al. Evaluation of drug-eluting beads versus conventional transcatheter arterial chemoembolization in patients with unresectable hepatocellular carcinoma: a systematic review and meta-analysis［J］. Clin Res Hepatol Gastroenterol, 2017, 41:75-85.
［12］ Sun J, Zhou G, Xie X, et al. Efficacy and safety of drug-eluting beads transarterial chemoembolization by CalliSpheres? in 275 hepatocellular carcinoma patients: results from the Chinese CalliSpheres? transarterial chemoembolization in liver cancer （CTILC） study［J］. Oncol Res, 2020, 28: 75-94.
［13］ Poyanli A, Rozanes I, Acunas B, et al. Palliative treatment of hepatocellular carcinoma by chemoembolization［J］. Acta radiol, 2001, 42: 602-607.
［14］张　申，张　磊，仲斌演，等．“TACE抵抗/失败”——需要全面认识［J］. 介入放射学杂志，2020，29：743-747．
［15］王文辉，李宝华，李　雷，等. 载药微球治疗中期原发性肝癌25例［J］. 介入放射学杂志，2021，30：270-274．
［16］ Vesselle G, Quirier-Leleu C, Velasco S, et al. Predictive factors for complete response of chemoembolization with drug-eluting beads （DEB-TACE） for hepatocellular carcinoma［J］. Eur Radiol, 2016, 26: 1640-1648.
［17］ Zhang X, Lin X, Qiu H, et al. An investigation of efficacy, safety, and prognostic factors of drug-eluting beads-transarterial chemoembolization operation with CalliSpheres? microspheres in treating Chinese hepatocellular carcinoma patients［J］. J Clin Lab Anal, 2019, 33: e22975.

相似文献/References:

[1]徐中琪,刘晟,许贇,等.完全性胸腹腔内脏反位合并原发性肝癌行经皮微波消融治疗4例[J].介入放射学杂志,2016,(06):546.
　XU Zhong-qi,LIU Sheng,XU Yun,et al.Percutaneous microwave ablation for primary hepatocellular carcinoma in patients with thoracic and abdominal situs inversus totalis: report of 4 cases [J].journal interventional radiology,2016,(01):546.
[2]仲斌演,王万胜,张 申,等.TACE抵抗的重新认知：一项中国医师协会介入医师分会发起的调查研究[J].介入放射学杂志,2023,32(07):642.
　ZHONG Binyan,WANG Wansheng,ZHANG Shen,et al.Re-understanding of TACE failure/refractoriness： a survey initiated by the Chinese College of Interventionalists[J].journal interventional radiology,2023,32(01):642.
[3]徐永康,付舒敏,李　丹,等.肝动脉灌注化疗联合系统治疗在原发性肝癌中的研究进展[J].介入放射学杂志,2023,32(01):94.
　XU Yongkang,FU Shumin,LI Dan,et al.Research progress in hepatic arterial infusion chemotherapy combined with systemic therapy for the treatment of primary hepatocellular carcinoma[J].journal interventional radiology,2023,32(01):94.

备注/Memo

备注/Memo:
（收稿日期：2021-11-05）
（本文编辑：新　宇）
更新日期/Last Update: 2023-02-13